4503:TSEAstellas Pharma Inc. Analysis

HASS is trading at 6,310 KRW, well below its 20‑day (7,141.5 KRW), 50‑day (6,888 KRW) and 200‑day (6,783.3 KRW) simple moving averages, signalling a technical weakness despite the model’s bullish trend flag. The RSI sits at 38.6, edging into oversold territory, while the MACD line is deep in the negative (-55) and the histogram is sharply negative, reinforcing a bearish momentum picture. Volume is on a downtrend and the stock is hovering just above a key support level of 6,300 KRW with a sizable resistance ceiling at 8,700 KRW, limiting upside potential in the near term. Fundamentally, revenue has contracted 13.5% year‑over‑year, free cash flow is negative, and the debt‑to‑equity ratio is an alarming 14.5, indicating heavy leverage and cash‑flow strain. The company’s dividend yield of 0.9% appears unsustainable given the zero payout ratio and negative cash generation. A discounted cash flow model places fair value around 3,775 KRW—less than 60% of the current price—suggesting the market is pricing in expectations far beyond the underlying economics. The Fear & Greed Index is at “Extreme Greed,” reflecting exuberant market sentiment that may be disconnected from the company’s deteriorating fundamentals. In summary, technical indicators, high volatility (≈59% 30‑day), elevated beta (1.21), and a weak balance sheet combine to paint a cautious outlook.